Erratum to: Human Plasma-Derived, Nanofiltered C1-Inhibitor Concentrate (Cinryze®), a Novel Therapeutic Alternative for the Management of Hereditary Angioedema Resulting From C1-Inhibitor Deficiency

Henriette Farkas · Lilian Varga

© The Author(s) 2012. This article is published with open access at Springerlink.com

Erratum to: Farkas H, Varga L. Human Plasma-Derived, Nanofiltered, C1-Inhibitor Concentrate (Cinryze®), a Novel Therapeutic Alternative for the Management of Hereditary Angioedema Resulting from C1-Inhibitor Deficiency. Biol Ther. 2012;2:002.

The authors of the above-mentioned paper noticed a few errors in the text, as reported. In the 'Pharmacokinetics' section, with regards to the C1 inhibitor, Cinryze® (ViroPharma Inc.), the maximum plasma concentration ($C_{\max}$) (units/mL) values should read 0.68 ± 0.08 ($n = 12$) versus 0.85 ± 0.12 ($n = 13$), and not 0.68 ± 0.08 ($n = 12$) versus 0.33 ± 0.20 ($n = 12$), as reported. The authors regret this error, and thank Springer Healthcare for publishing the correction.